NEWS

ImmunityBio

ImmunityBio Stock Climbs 7% as Record $44M Q1 Revenue from ANKTIVA Fuels Biotech Rally

Shares of ImmunityBio Inc. rose sharply midday Thursday as the commercial-stage immunotherapy company reported record preliminary first-quarter 2026 net product revenue of approximately $44.2 million from its flagship bladder cancer therapy ANKTIVA, marking a 168% increase from the same period last year and underscoring accelerating commercial traction despite a recent FDA warning on promotional materials.
More news

Pages

  • Prev
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • Next